Abeona Therapeutics Inc
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +39.1% | -27.3% | +16.7% | +0.9% | -1.8% | +147.0% | -48.0% | +519.2% | -224.5% | – | – | – | – | – | – | – | -57.1% | +0.0% | -100.0% | – | – | -88.5% | +189.0% | -100.0% | – | +0.0% | +5,047.1% | -100.0% | – | -100.0% | – | – | – | -100.0% | – | -100.0% | – | +60.9% | +30.5% | – | |
| – | +13.7% | -62.4% | +164.2% | -43.6% | +74.1% | +43.0% | -3.0% | +66.1% | -28.0% | +23.9% | -82.5% | +430.7% | -12.0% | -29.0% | -10.4% | +30.4% | +16.0% | -88.3% | +1.3% | -1.4% | +1,081.1% | -17.6% | -33.5% | -84.5% | +487.3% | -86.1% | +77.4% | -98.1% | +2,303.3% | +0.4% | +130.2% | -56.7% | +7.5% | +5.0% | -87.7% | +388.0% | +481.4% | +25.7% | +17.2% | – | |
| – | +39.1% | -885.9% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -377.2% | – | – | – | – | – | – | – | – | – | -101.6% | – | – | – | – | – | – | – | -262.7% | – | +99.6% | +39.7% | – | |
| – | +10.6% | -27.6% | +164.2% | -43.6% | +74.1% | +43.0% | -3.0% | +66.1% | -20.8% | +12.7% | +38.9% | -33.1% | -0.4% | +265.4% | -84.6% | +30.4% | +16.0% | -10.0% | +2.6% | +6.1% | +41.7% | -7.0% | -44.2% | -17.5% | +14.2% | +28.2% | +6.0% | -16.1% | +3.2% | -2.3% | +27.9% | -3.0% | +0.6% | +10.5% | -40.2% | -29.1% | +59.2% | +42.4% | -47.5% | – | |
| – | +17.2% | +7.8% | -12.6% | -18.0% | +43.7% | -7.5% | +60.8% | +7.4% | +53.5% | -25.8% | -0.8% | -16.3% | +0.7% | +35.4% | -13.6% | -20.0% | +66.9% | -15.1% | -17.5% | +12.2% | -24.6% | -3.6% | -18.1% | +12.4% | +46.1% | -29.7% | +25.6% | -17.2% | +40.3% | +22.2% | +21.4% | -25.9% | +19.9% | +27.5% | +75.2% | +12.6% | -2.8% | +3.8% | -18.8% | – | |
| – | +13.6% | -46.3% | +164.6% | -73.4% | +41.4% | -6.4% | +61.1% | +11.3% | +237.8% | +3.0% | +15.0% | -19.5% | -61.4% | +508.2% | -69.8% | -57.7% | +231.1% | -16.5% | -6.0% | +8.4% | +147.8% | -71.8% | -80.8% | +369.0% | -29.3% | +81.5% | +3.7% | -9.4% | +10.5% | +14.8% | +24.7% | -14.1% | +3.6% | +24.1% | +17.1% | +1.9% | +8.3% | +10.6% | -26.0% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +100.0% | +0.0% | +50.0% | -33.3% | -50.0% | +200.0% | +0.0% | +0.0% | -33.3% | +0.0% | -100.0% | – | – | +50.0% | +33.3% | +65.9% | +4.6% | +2.3% | +5.6% | -54.5% | -90.2% | +200.0% | -0.5% | -21.5% | +13.4% | -43.3% | +2.0% | +1.9% | +3.8% | +773.4% | +12.6% | +2.8% | -1.8% | -7.8% | -4.1% | -5.9% | -1.9% | -6.1% | -16.1% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -508.7% | – | – | – | -116.4% | – | – | – | – | |
| – | -145.8% | – | +320.5% | -87.2% | +1,333.3% | -48.2% | +103.2% | +57.7% | +6.6% | -6.4% | -89.6% | +432.7% | +37.2% | +57.9% | -54.8% | +24.7% | -88.2% | -62.5% | -46.7% | +8,437.5% | -90.2% | +198.5% | -686.5% | – | -5,564.5% | – | -15.4% | +10.4% | -14.3% | +0.5% | -344.9% | – | – | – | – | -198.0% | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -508.7% | – | – | – | -104.7% | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -410.4% | – | – | – | -114.7% | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.